The Biostatistics Shared Resource of the Mayo Clinic Cancer Center (MCCC) has provided expert statistical collaboration with MCCC investigators for over 30 years. The purpose of the resource is to provide statistical and biomathematical collaboration for the development and conduct of peer-reviewed cancer research generated by investigators in the MCCC. This research ranges from the bench to the bedside to the population, and encompasses basic science, clinical trials, epidemiologic research, and other translational and educational research. The primary usage of the funds provided to the resource by the CCSG is to support statistical and mathematical collaboration on pilot projects, for assistance to investigators in developing approved research projects not otherwise funded but leading towards external funding, and to support unanticipated needs for statistical collaboration on MCCC approved projects. Over the 30 year history of the Biostatistics Shared Resource, the group has undergone a natural and deliberate evolution and expansion, spurred by the expanding research activities of the MCCC. The Biostatistics Shared Resource has multiple focus areas (teams) tied together into a well-organized, efficient core. These are: (I) a Clinical Trials team responsible for cancer clinical trials, associated translational research, interventional psychosocial research, and imaging, together with patient and public education research projects, (II) a Population Science team responsible for providing statistical collaboration and data management support for cancer observational studies, including genetic and molecular epidemiology, (III) a Quality of Life team responsible for providing general and specific advice, measurement tools, and analysis for MCCC investigators who are investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others, and (IV) a Biomathematics team that provides collaborative expertise in the mathematical aspects of imaging, data processing and analysis, mathematical modeling (e.g. of tumor growth), and general mathematical or algorithmic issues. These groups work efficiently and effectively together to provide statistical and biomathematical collaboration to Mayo Clinic Cancer Center investigators across all three MCCC campuses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-33
Application #
7414490
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
33
Fiscal Year
2007
Total Cost
$804,754
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8
O'Mara, Tracy A; Glubb, Dylan M; Amant, Frederic et al. (2018) Identification of nine new susceptibility loci for endometrial cancer. Nat Commun 9:3166
Wallace, Sumer K; Halverson, Jessica W; Jankowski, Christopher J et al. (2018) Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. Obstet Gynecol 131:891-898
Shrestha, Shikshya; Zhang, Cheng; Jerde, Calvin R et al. (2018) Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase. Clin Pharmacol Ther 104:709-718
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Geller, James I; Fox, Elizabeth; Turpin, Brian K et al. (2018) A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315). Cancer 124:4548-4555
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547

Showing the most recent 10 out of 1129 publications